Journal of Clinical and Cellular Immunology
Open Access

Driving behaviors of the stakeholders involved in vaccine value chain through technological advances

Joint Event on 36^th Euro Global Summit and Expo on Vaccines & Vaccination & 6^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

June 03-04, 2019 London, UK

Pierre A Morgon

MRGN Advisors, Switzerland

Keynote: J Clin Cell Immunol

Abstract :

The vaccine segment is anticipated to be one of the fastest growing one of the healthcare industry and several leading firms have stepped up vaccine investments in recent years. Unlike therapeutic agents, vaccines are administered to healthy individuals only once or very infrequently during a life time. Vaccines generate well-documented positive externalities, yet their poor awareness and acceptability among vaccine end-users may contribute to resurgence of transmissible diseases and consequently trigger governmental interventions such as mandating vaccination. In addition to technical and clinical development per the highest quality standards, bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of stakeholders along the entire value chain and addressing their respective purchasing behavioral drivers. Against a backdrop of anti-vaccination buzz and vaccine fatigue, successful global launch and sustainable usage of a vaccine requires the development of a multi-pronged strategy addressing all aspects in relation to acceptability (e.g. the motivation to immunize despite the quasi-disappearance of the disease), accessibility (e.g. supply chain services), availability (e.g. mechanisms ensuring reliability of supply) and affordability (e.g. tiered pricing policy taking country differences in per capita income into account). Leveraging novel technological advances can positively influence the ability to activate these levers successfully.

Biography :

Pierre A. MORGON is the Founder of MRGN Advisors. He is Chairman of the boards of Theradiag and of Virometix and he is Non-Executive Director at the boards of Eurocine Vaccines, Vaccitech and Univercells. He is also Regional Partner for Switzerland at Mérieux Equity Partners. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs. .

E-mail: pm@mrgnadvisors.com